Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Key Points

• Analysts' consensus: Nine analysts give Jade Biosciences a "Moderate Buy" consensus (1 sell, 1 hold, 5 buy, 2 strong buy) with an average 1‑year target price of $29.50.
• Earnings and outlook: The company last reported ($0.11) EPS, beating estimates by $0.34, but analysts still forecast a negative full‑year EPS of about ‑2.21.
• Institutional interest: Large investors have been adding shares—RA Capital grew its stake ~245.6% to 3.67M shares and new/expanded positions were reported from Baker Bros., Remedium, Aberdeen and Marshall Wace—signaling notable institutional accumulation.

Shares of Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $29.50.

JBIO has been the subject of several recent analyst reports. Guggenheim lifted their price target on Jade Biosciences from $17.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, March 11th. William Blair upgraded Jade Biosciences to a "strong-buy" rating in a report on Monday, March 9th. Weiss Ratings upgraded Jade Biosciences from a "sell (d-)" rating to a "sell (d)" rating in a report on Friday. Lifesci Capital upgraded Jade Biosciences to a "strong-buy" rating in a report on Friday, March 6th. Finally, Zacks Research upgraded Jade Biosciences from a "strong sell" rating to a "hold" rating in a report on Wednesday, April 8th.

Jade Biosciences Price Performance

NASDAQ:JBIO opened at $24.98 on Monday. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of -5.42 and a beta of 1.03. Jade Biosciences has a 1-year low of $6.57 and a 1-year high of $96.95. The firm's fifty day moving average price is $16.14 and its 200 day moving average price is $14.16.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last announced its quarterly earnings data on Friday, March 6th. The company reported ($0.11) earnings per share for the quarter, beating analysts' consensus estimates of ($0.45) by $0.34. As a group, analysts expect that Jade Biosciences will post -2.21 earnings per share for the current fiscal year.

Institutional Trading of Jade Biosciences

A number of institutional investors have recently modified their holdings of JBIO. RA Capital Management L.P. grew its holdings in shares of Jade Biosciences by 245.6% during the 4th quarter. RA Capital Management L.P. now owns 3,671,083 shares of the company's stock worth $56,645,000 after purchasing an additional 2,608,757 shares during the period. Baker BROS. Advisors LP purchased a new position in Jade Biosciences in the 4th quarter worth approximately $25,323,000. Remedium Capital Partners LLC purchased a new position in Jade Biosciences in the 4th quarter worth approximately $24,345,000. Aberdeen Group plc purchased a new position in Jade Biosciences in the 4th quarter worth approximately $13,382,000. Finally, Marshall Wace LLP boosted its holdings in Jade Biosciences by 2,198.5% in the 4th quarter. Marshall Wace LLP now owns 875,273 shares of the company's stock worth $13,505,000 after acquiring an additional 837,193 shares during the period.

Jade Biosciences Company Profile

Jade Biosciences, Inc is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments.

The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.